Addition of anti-CD25 to thymoglobulin for induction therapy: delayed return of peripheral blood CD25-positive population

作者:Sageshima Junichiro; Ciancio Gaetano; Gaynor Jeffrey J; Chen Linda; Guerra Giselle; Kupin Warren; Roth David; Ruiz Phillip; Burke George W*
来源:Clinical Transplantation, 2011, 25(2): E132-E135.
DOI:10.1111/j.1399-0012.2010.01360.x

摘要

An anti-CD25 monoclonal antibody was added to thymoglobulin for induction therapy in simultaneous pancreas/kidney (SPK) recipients. T-cell subsets including CD3 and CD25 were assessed by flow cytometry analysis in the peripheral blood of SPK (n = 88), and for comparison kidney transplant (KT) recipients were assessed. KT recipients were treated with daclizumab (anti-CD25) alone (five doses; 1 mg/kg) (n = 27) or thymoglobulin alone (4-7 doses; 1 mg/kg) (n = 23). SPK recipients received daclizumab (two doses; 1 mg/kg) in addition to thymoglobulin (five doses; 1 mg/kg). The return of peripheral blood CD25+ cells was delayed for 45 d post-transplantation in the SPK recipients where anti-CD25 was added to thymoglobulin, compared to those KT recipients with thymoglobulin alone. This strategy may result in reduced allogeneic (donor-specific) T effector cells at the time of solid organ transplantation.

  • 出版日期2011-4